# Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

> **NCT02452216** · EARLY_PHASE1 · COMPLETED · sponsor: **Michael Iv** · enrollment: 10 (actual)

## Conditions studied

- Brain Injury
- Central Nervous System Degenerative Disorder
- Central Nervous System Infectious Disorder
- Central Nervous System Vascular Malformation
- Hemorrhagic Cerebrovascular Accident
- Ischemic Cerebrovascular Accident
- Primary Brain Neoplasm
- Brain Cancer
- Brain Tumors

## Interventions

- **DRUG:** Ferumoxytol
- **OTHER:** Tissue Analysis
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT02452216
- **Lead sponsor:** Michael Iv
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-10
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-01-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452216, "Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02452216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*